跳至主要内容
临床试验/NCT01736423
NCT01736423已完成3 期

A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome

Astellas Pharma Inc0 个研究点目标入组 151 人开始时间: 2012年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
151
主要终点
Change in weekly average of scores of stool form

研究概览

简要总结

To evaluate the efficacy and safety of YM060 once daily for female patients with diarrhea-predominant irritable bowel syndrome (D-IBS) for a long-term period (up to 52 weeks).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 64 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Female patients who meet the following criteria:
  • Patients satisfying the Rome III Diagnostic Criteria
  • Patients whose ≥25% of stools were loose or watery and <25% of them were hard or lumpy stools
  • Patients who have abdominal pain or discomfort
  • Patients in whom after occurrence of IBS symptoms the following tests were conducted and in whom no organic changes were observed Pancolonoscopy or contrast enema

排除标准

  • Patients who meet any of the following criteria:
  • Patients with a history of surgical resection of the stomach,gallbladder, small intestine or large intestine
  • Patients with a history or current evidence of inflammatory bowel disease
  • Patients with a history or current evidence of colitis ischemic
  • Patients with concurrent infectious enteritis
  • Patients with concurrent hyperthyroidism or hypothyroidism
  • Patients with concurrent active peptic ulcer
  • Patients with other concurrent disease that may affect the digestive tract passage or large intestinal function or that is likely to interfere with proper assessment of IBS abdominal pain/discomfort

研究组 & 干预措施

Female Patients with D-IBS

Experimental

干预措施: YM060 (Drug)

结局指标

主要结局

Change in weekly average of scores of stool form

时间窗: up to 52 weeks

Rate of days without urgency

时间窗: up to 52 weeks

Rate of days without feeling of incomplete bowel movement

时间窗: up to 52 weeks

Monthly responder rate of stool form normalization

时间窗: up to 52 weeks

Monthly responder rate of global assessment of improvement of abnormal bowel habits

时间窗: up to 52 weeks

Monthly responder rate of global assessment of relief of overall IBS symptoms

时间窗: up to 52 weeks

Change in weekly average of stool frequency

时间窗: up to 52 weeks

Monthly responder rate of global assessment of relief of abdominal pain/discomfort

时间窗: up to 52 weeks

Change in entire Japanese version of Irritable Bowel Syndrome Quality of Life (IBS-QOL-J) scores and pairwise IBS-QOL-J scores on the sub-scales

时间窗: 4, 8, 12, 28 and 52 weeks

Change in weekly average of scores of severity of abdominal pain/discomfort

时间窗: up to 52 weeks

次要结局

  • Safety assessed through AEs and clinical laboratory values(up to 52 weeks)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验